# US 6,730,520 B2 · Low fluorescence assay platforms and related methods for drug discovery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,520 B2
- Document ID: US6730520B2
- Status: Granted
- Kind: B2
- Application number: 10/120,644
- Filed: 2002-04-09
- Published: 2002-10-24
- Granted: 2004-05-04
- Earliest claimed: 1998-02-24
- Assignees: Aurora Discovery, Inc.
- Inventors: Peter J. Coassin; Alec Tate Harootunian; Andrew A. Pham; Harry Stylli; Roger Y. Tsien
- Web page: https://patentgrep.com/patent/US6730520B2

## CPC

- B01L 3/5085: {for multiple samples, e.g. microtitration plates}
- B01L 9/523: {for multisample carriers, e.g. used for microtitration plates}
- C12M 23/12: {Well or multiwell plates (C12M25/04 takes precedence)}
- C12Q 1/00: Measuring or testing processes involving enzymes, nucleic acids or microorganisms (measuring or testing apparatus with condition measuring or sensing means, e.g. colony counters, C12M1/34); Compositions therefor; Processes of preparing such compositions
- G01N 21/6428: {Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" (in vivo A61B5/00; immunoassay G01N33/53)}
- G01N 21/6452: {Individual samples arranged in a regular 2D-array, e.g. multiwell plates}
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/542: with steric inhibition or signal modification, e.g. fluorescent quenching
- B01J 2219/00315: Microtiter plates
- B01J 2219/00317: Microwell devices, i.e. having large numbers of wells
- B01J 2219/00659: Two-dimensional arrays
- B01J 2219/00707: separated from the reactor apparatus
- B01J 2219/0072: Organic compounds
- B01L 2300/021: Identification, e.g. bar codes
- B01L 2300/0829: Multi-well plates; Microtitration plates
- B01L 2300/12: Specific details about materials
- C40B 60/14: for creating libraries
- G01N 1/30: Staining; Impregnating {; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis}
- G01N 21/03: Cuvette constructions
- G01N 2021/0346: {Capillary cells; Microcells}
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)

## Abstract

One aspect of the present invention is a multi-well platform for fluorescence measurements, comprising a plurality of wells within a frame, wherein the multi-well platform has low fluorescence background. Another aspect of the present invention is a system for spectroscopic measurements, comprising reagents for an assay and a multi-well platform for fluorescence measurements. A further aspect of the present invention is a method for detecting the presence of an analyte in a sample contained in a multi-well platform by detecting light emitted from the sample. Another aspect of the present invention is a method from identifying a modulator of a biological process or target in a sample contained in a multi-well platform by detecting light emitted from the sample. Another aspect of the present invention is a composition identified by this method. A further aspect of the present invention is a method to identify a therapeutic. A further aspect of the present invention is a method of testing a therapeutic for therapeutic activity and toxicology by identifying a therapeutic using a method of the present invention and monitoring the toxicology and efficacy of the therapeutic in an in vivo model.

## Claims

### Claim 1

A method for detecting the presence of an analyte in a sample contained in a multi-well platform by detecting light emitted from the sample, said method comprising the steps of:
a) exciting at least one sample with radiation of a first wavelength;
b) wherein at least one sample suspected of containing an analyte is placed into at least one well of a multi-well platform comprising:
i) a plurality of wells, each well comprising:
a) a wall having less fluorescence than a polystyrene-wall of at least about 90 percent of said wall's thickness, and
b) a bottom, and
c) measuring the emission of radiation of a second wavelength emitted from said at least one sample,
d) wherein the amount of radiation of said second wavelength measured is related to the presence or absence of said analyte.

### Claim 2 (depends on 1)

The method of claim 1 wherein said sample is excited through said bottom of said well.

### Claim 3

A method of testing a therapeutic for therapeutic activity and toxicology comprising the steps of:
a) identifying a therapeutic using the method comprising the steps of:
i) contacting a test chemical suspected of having modulating activity of a biological process or target with a biological process or target in a multi-well platform comprising:
a) a plurality of wells, each well comprising:
(1) a wall having less fluorescence than a polystyrene-wall of at least about 90 percent of said wall's thickness, and
(2) a bottom, and
ii) exciting said sample with radiation of a first wavelength,
iii) measuring the emission of radiation of a second wavelength emitted from said sample, and
iv) wherein said test chemical has a modulating activity with respect to said process or target,
b) monitoring the toxicology of said therapeutic in an in vivo model, and
c) monitoring the efficacy of said therapeutic in an in vivo model.
